Most patients with pancreatic ductal adenocarcinoma (PDAC) present with symptomatic,
surgically unresectable disease. Although the goal of early detection of PDAC is laudable …

The secreted glycoprotein leucine-rich α-2 glycoprotein 1 (LRG1) was first described as a
key player in pathogenic ocular neovascularization almost a decade ago. Since then, an …

The earlier diagnosis of cancer is one of the keys to reducing cancer deaths in the future.
Here we describe our efforts to develop a noninvasive blood test for the detection of …

Background & Aims There is substantial interest in liquid biopsy approaches for cancer early
detection among subjects at risk, using multi-marker panels. CA19-9 is an established …

Simple Summary Stroma modifications observed in solid cancer are now recognized as
critical events for cancer progression and as potential therapeutic or diagnostic targets. The …

To observe the diagnostic values of circular RNAs (circRNAs), their expression profiles
between gastric cancer patients' plasma and healthy controls were first assessed by …

Markers are needed to facilitate early detection of pancreatic ductal adenocarcinoma
(PDAC), which is often diagnosed too late for effective therapy. Starting with a PDAC cell …

Pancreatic ductal adenocarcinoma (PDAC) is usually detected late in the disease process.
Clinical workup through imaging and tissue biopsies is often complex and expensive due to …

Pancreatic cancer is accompanied by a fibrotic reaction that alters interactions between
tumor cells and the stroma to promote tumor progression. Consequently, strategies to target …

Tumor cell–derived extracellular vesicles (EVs) are being explored as circulating
biomarkers, but it is unclear whether bulk measurements will allow early cancer detection …